Second Sight touts publication of 3-year Argus II study

This study validates the positive feedback we’ve been receiving from our recipients all along,” CEO Will McGuire said in prepared remarks. The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining with electrical pulses, which allows for the perception of light patterns to the brain, the company said. The post Second Sight touts publication of 3-year Argus II study appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Optical/Ophthalmic Second Sight Medical Products Inc. Source Type: news